Avadel Pharmaceuticals PLC (AVDL) — Cash Flow Reinvestment Rate

Latest as of September 2025: 0.36x

Avadel Pharmaceuticals PLC (AVDL) has a Cash Flow Reinvestment Rate of 0.36x as of September 2025, reinvesting $8.44 Million (capex $10.76K plus investments $-8.43 Million) from operating cash flow of $23.26 Million. Check AVDL operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.

Reinvestment Rate

0.36x
(Capex + Investments) / Operating CF

Total Reinvested

$8.44 Million
Capex + Investments

Operating Cash Flow

$23.26 Million
USD

Capital Expenditures

$10.76K
USD

Avadel Pharmaceuticals PLC Cash Flow Reinvestment Rate (2002–2017)

Historical reinvestment intensity for Avadel Pharmaceuticals PLC across 6 annual periods. Explore Avadel Pharmaceuticals PLC cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.

Annual Cash Flow Reinvestment Rate for Avadel Pharmaceuticals PLC (2002–2017)

Year-by-year capital reinvestment analysis for Avadel Pharmaceuticals PLC. For live market cap and broader valuation context, see Avadel Pharmaceuticals PLC market cap and net worth.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2017 5.50x $91.71 Million $16.66 Million $53.70 Million ▲ +179.2%
2016 1.97x $37.26 Million $18.90 Million $1.20 Million ▲ +423.7%
2015 0.38x $31.73 Million $84.29 Million $1.63 Million ▲ +74.3%
2009 0.22x $1.77 Million $8.20 Million $1.77 Million ▼ -7.0%
2003 0.23x $2.84 Million $12.23 Million $2.84 Million ▲ +42.0%
2002 0.16x $1.44 Million $8.77 Million $1.44 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow